SCHEMBL25754416

SCHEMBL25754416

CC#CC(N)CCCOCCN1CCCCC1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 9/20 0.38
SLC6A2 P23975 2/20 0.37
HRH1 P35367 2/20 0.37
CHRM2 P08172 1/20 0.37
ADRA2C P18825 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
KCNH2 Q12809 1/20 0.37
CACNA1C Q13936 1/20 0.37
SCN5A Q14524 1/20 0.37
CHRM4 P08173 1/20 0.36
HTR2C P28335 1/20 0.36
HTR7 P34969 1/20 0.36
TMEM97 Q5BJF2 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
MAPT P10636 1/20 0.34
HTT P42858 3/20 0.33
KDM4E B2RXH2 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25754413 0.91 MAPT (0.36) HRH3SLC6A2HRH1CHRM2ADRA2C
SCHEMBL25754436 0.90 KDM4E (0.36) HRH3MAPTHTTKDM4E
SCHEMBL25754417 0.84 HTT (0.39) HRH3MAPTHTTKDM4E
SCHEMBL25754394 0.83 HRH3 (0.35) HRH3MAPTHTTKDM4E
SCHEMBL25754250 0.82 HRH3 (0.39) HRH3SLC6A2HRH1CHRM2ADRA2C
SCHEMBL25754573 0.78 HRH3 (0.38) HRH3SLC6A2HRH1CHRM2ADRA2C
SCHEMBL25754591 0.77 HRH3 (0.38) HRH3MAPTHTTKDM4E
SCHEMBL25754249 0.77 HRH3 (0.38) HRH3MAPTHTTKDM4E
SCHEMBL25754258 0.76 KDM4E (0.39) HRH3MAPTHTTKDM4E
SCHEMBL25754568 0.73 HRH3 (0.43) HRH3SLC6A2HRH1CHRM2ADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM UCHL3, UBE2L3, ADAM33 HRH3 1596/4885SLC6A2 4723/4885HRH1 1557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.